Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- SHPH
- Price
- 2.36
- Stock movement up
- +0.13 (8.97%)
- Company name
- Shuttle Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 1.69M
- Ent value
- -1.23M
- Price/Sales
- 87.60
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -92.39%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2025-12-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SHPH does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 87.60 |
| Price to Book | - |
| EV to Sales | -63.53 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.07M |
| EPS (TTM) | -4.79 |
| FCF per share (TTM) | -5.01 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.75K |
| Gross profit (TTM) | -3.81K |
| Operating income (TTM) | -10.91M |
| Net income (TTM) | -10.71M |
| EPS (TTM) | -4.79 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -66.32% |
| Operating margin (TTM) | -189730.64% |
| Profit margin (TTM) | -186242.92% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.09M |
| Net receivables | 0.00 |
| Total current assets | 3.27M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 246.71K |
| Total assets | 3.54M |
| Accounts payable | 1.47M |
| Short/Current long term debt | 667.33K |
| Total current liabilities | 1.96M |
| Total liabilities | 2.15M |
| Shareholder's equity | 1.39M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -11.20M |
| Capital expenditures (TTM) | 6.00 |
| Free cash flow (TTM) | -11.20M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -767.86% |
| Return on Assets | -302.16% |
| Return on Invested Capital | -567.56% |
| Cash Return on Invested Capital | -593.73% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.36 |
| Daily high | 1.60 |
| Daily low | 1.36 |
| Daily Volume | 45K |
| All-time high | 10480.00 |
| 1y analyst estimate | - |
| Beta | 0.56 |
| EPS (TTM) | -4.79 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| SHPH | S&P500 | |
| Current price drop from All-time high | -99.98% | -0.89% |
| Highest price drop | -99.99% | -19.00% |
| Date of highest drop | 25 Nov 2025 | 8 Apr 2025 |
| Avg drop from high | -99.89% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 290 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.69M
Marketcap category
Small-cap
Description
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
Employees
9
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page